Nature Communications (Sep 2022)

The clinical drug candidate anle138b binds in a cavity of lipidic α-synuclein fibrils

  • Leif Antonschmidt,
  • Dirk Matthes,
  • Rıza Dervişoğlu,
  • Benedikt Frieg,
  • Christian Dienemann,
  • Andrei Leonov,
  • Evgeny Nimerovsky,
  • Vrinda Sant,
  • Sergey Ryazanov,
  • Armin Giese,
  • Gunnar F. Schröder,
  • Stefan Becker,
  • Bert L. de Groot,
  • Christian Griesinger,
  • Loren B. Andreas

DOI
https://doi.org/10.1038/s41467-022-32797-w
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 10

Abstract

Read online

Understanding how small molecules bind to pathological aggregates is of importance for therapeutic and diagnostic development in diseases such as Parkinson’s Disease. Here, the authors reveal a binding site of anle138b to lipid-induced α-synuclein fibrils.